Status:
COMPLETED
Study of the Efficacy and Safety of MEDI4893
Lead Sponsor:
MedImmune LLC
Collaborating Sponsors:
Innovative Medicines Initiative
Antibacterial Resistance Leadership Group
Conditions:
Staphylococcus Aureus Pneumonia
Eligibility:
All Genders
18-130 years
Phase:
PHASE2
Brief Summary
Clinical trial looking at safety and efficacy of MEDI4893 in prevention of pneumonia caused by Staphylococcus aureus in high-risk patients
Eligibility Criteria
Inclusion
- Colonized with Staphylococcus aureus, expected to require prolonged intubation and mechanical ventilation, without any evidence of active pneumonia.
Exclusion
- Staphylococcal disease at randomisation; lung injury score consistent with pneumonia; current lung disease; chronic tracheostomy patients; currently receiving systemic anti-staphylococcal antibiotics; moribund patients.
Key Trial Info
Start Date :
October 10 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 2 2018
Estimated Enrollment :
213 Patients enrolled
Trial Details
Trial ID
NCT02296320
Start Date
October 10 2014
End Date
October 2 2018
Last Update
December 23 2019
Active Locations (49)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Atlanta, Georgia, United States, 30322
2
Research Site
Detroit, Michigan, United States, 48202
3
Research Site
Arlon, Belgium, 6700
4
Research Site
Brussels, Belgium